Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice

被引:15
作者
Karlsson, Agneta [2 ]
Jagervall, Ake [3 ]
Utkovic, Helena [2 ]
Karlsson, Lisa [2 ]
Rehnstrom, Erika [3 ]
Fredin, Maria Fritsch [2 ]
Gillberg, Per-Goran [2 ]
Jansson, Liselotte [2 ]
Michaelsson, Erik [2 ]
Melgar, Silvia [1 ]
机构
[1] Natl Univ Ireland Univ Coll Cork, Biosci Inst, Alimentary Pharmabiot Ctr, Cork, Ireland
[2] AstraZeneca R&D, Dept Integrat Pharmacol, Molndal, Sweden
[3] AstraZeneca R&D, Dept Mol Pharmacol, Molndal, Sweden
关键词
R-848/resiquimod; mouse; colon; cytokines; prednisolone; TNF;
D O I
10.1016/j.bbrc.2007.12.046
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Imidazoquinoline compounds, such as resiquimod (R-848), are well known topically active immune modifiers that bind to toll-like receptor 7 (TLR7). The aim of this study was to characterize the R-848 induced inflammatory response in mice and to validate the response using methyl-prednisolone and anti-TNF antibody. Intra-colonic application of R-848 to BALB/c mice induced a systemic transient elevation of TNF, CXCL1, IL-6, and IL-12p40 and a colonic elevation of cytokines/chemokines and iNOS, without infiltration of immune cells or epithelial destruction. Treatment with methyl-prednisolone or anti-TNF antibody attenuated the systemic (TNF, IL-6, IL-12p40, and CXCL1) and local (colonic TNF and iNOS mRNA expression) response induced by R-848. In summary, intra-colonic administration of R-848 induces an acute systemic and local inflammatory response, which can be attenuated by steroids or anti-TNF antibody. We suggest that the R-848 inflammatory model can be useful in future validation of new drugs for gastrointestinal inflammatory conditions. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 31 条